Comparison of Anticardiolipin Antibodies Titer in Preeclampsia and Normal Pregnancy: A CaseControl Study
DOI:
https://doi.org/10.61841/g59dgk92Keywords:
Preeclampsia, Anti-cardiolipin Antibodies, Normal PregnancyAbstract
Background and Aim: Regarding the high prevalence of pre-eclampsia and its complications and also due to conflicting reports about the role of antiphospholipid antibodies, particularly anticardiolipin antibody, the aim of this study was to compare the anticardiolipin antibody titers in pre-eclampsia and normal pregnancy.
Material and Methods: In this cross-sectional study, 220 pregnant women in their third trimester were evaluated in Zahedan Ali ebn Abi Talib (AS) hospital in 2013. Participants were divided into two groups: preeclamptic pregnant and normal pregnant as the control group. The sampling method was simple and available. Anticardiolipin IgG and IgM levels were measured in two groups. Samples were analyzed by simple and available methods. An independent t-test was used for data analysis. A p-value less than 0.05 was considered significant.
Results: The mean age of pregnant women was 26.1±6.2 years. The gestational age was 37 ± ±2.1 and 1.9 weeks in the control and preeclampsia groups, respectively (P = 0.14). The mean IgM titer of anticardiolipin antibody in the preeclampsia group was 1.85±0.84 μg/L and in the control group 2.21±1.61 μg/L, with no significant difference found between the two groups (P=0.53). The mean IgG titer of anti-cardiolipin antibody in the preeclampsia group was 2.48±1.16 μg/L and in the control group 2.13±0.54 μg/L, and again no statistically significant difference was observed (P=0.34).
Conclusions: There was no correlation between anti-cardiolipin antibody titers in pregnant women with preeclampsia compared with normal pregnant women.
Downloads
References
1. Gonzalez-Echavarri C, Villar I, Ugarte A, Larrieta R, Ruiz-Irastorza G. Prevalence and Significance of Persistently Positive Antiphospholipid Antibodies in Women with Preeclampsia. The Journal of Rheumatology. 2015;42(2):210-3.
2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. The Lancet. 2006;367(9516):1066-74.
3. Petri M. Epidemiology of the antiphospholipid antibody syndrome. Journal of Autoimmunity. 2000;15(2):145-51.
4. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine. 1993;72(2):113-24.
5. Tsapanos V, Kanellopoulos N, Cardamakis E, Fotopoulos A, Tzingounis V, Schinas V, et al. Anticardiolipin
antibody levels in healthy pregnant and non-pregnant women. Archives of gynecology and obstetrics. 2000;263(3):111-5.
6. Matthiesen LS, Berg G, Ernerudh J, Skogh T. A prospective study on the occurrence of autoantibodies in
low-risk pregnancies. European Journal of Obstetrics & Gynecology and Reproductive Biology.
1999;83(1):21-6.
7. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Greaves M, et al. Screening for thrombophilia in high-risk
situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic
Assessment of Thrombophilia Screening (TREATS) study. NIHR Health Technology Assessment
Program: Executive Summaries: NIHR Journals Library; 2006.
8. de Jesus GR, Agmon-Levin N, Andrade CA, Andreoli L, Chighizola CB, Porter TF, et al. 14th International
Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome.
Autoimmunity reviews. 2014;13(8):795-813.
9. Galli M, Barbui T, Comfurius P, Maassen C, Hemker H, Zwaal R, et al. Anticardiolipin antibodies (ACA)
directed not to cardiolipin but to a plasma protein cofactor. The Lancet. 1990;335(8705):1544-7.
10. Yamamoto T, Yoshimura S, Geshi Y, Sakamoto T, Ogino M, Kobayashi T, et al. Anticardiolipin antibody in
preeclampsia. Japanese Journal of Clinical Immunology. 1992;15(5):467-74.
11. Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, et al. Maternal thrombophilia and
the risk of recurrence of preeclampsia. American Journal of Obstetrics and Gynecology. 2009;200(1):46.e1-.
e5.
12. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a
complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein
H). Proceedings of the National Academy of Sciences. 1990;87(11):4120-4.
13. Matsuura E. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet.
1990;336:177-8.
14. Kupferminc MJ. Thrombophilia and pregnancy. Reproductive Biology and Endocrinology. 2003;1(1):111.
15. Ganzevoort W, Rep A, De Vries JI, Bonsel GJ, Wolf H, PETRA-Investigators ft. Relationship between
thrombophilic disorders and types of severe early-onset hypertensive disorders of pregnancy. Hypertension in
pregnancy. 2007;26(4):433-45.
16. Dreyfus M, Hedelin G, Kutnahorsky R, Lehmann M, Viville B, Langer B, et al. Antiphospholipid antibodies
and preeclampsia: a case-control study. Obstetrics & Gynecology. 2001;97(1):29-34.
17. do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with
preeclampsia: a systematic review and meta-analysis. Obstetrics & Gynecology. 2010;116(6):1433-43.
18. Schreiber K, Hunt BJ. Managing antiphospholipid syndrome in pregnancy. Thrombosis research.
2019;181:S41-S6.
19. Hristoskova S, Holzgreve W, Hahn S. Antiphospholipid and AntiDNA Antibodies Are Not Associated with
the Elevated Release of Circulatory Fetal DNA in Pregnancies Affected by Preeclampsia. Hypertension in
pregnancy. 2004;23(3):257-68.
20. Lee RM, Brown MA, Branch DW, Ward K, Silver RM. Anticardiolipin and anti–β2-glycoprotein-I antibodies in preeclampsia. Obstetrics & Gynecology. 2003;102(2):294-300.
21. Benedict N, Augustina AO, Emefiele AM, Alexander NI. Antiphospholipid Antibodies in Women with Preeclampsia Seen at the University of Benin Teaching Hospital, Benin City, Nigeria.
22. Kestlerová A, Feyereisl J, Frisová V, Měchurová A, Šůla K, Zima T, et al. Immunological and biochemical markers in preeclampsia. Journal of Reproductive Immunology. 2012;96(1-2):90-4.
23. Yamamoto T, Takahashi Y, Geshi Y, Sasamori Y, Mori H. Anti-Phospholipid Antibodies in Preeclampsia and Their Binding Ability for Placental Villous Lipid Fractions. Journal of Obstetrics and Gynaecology Research. 1996;22(3):275-83.
24. Fialova L, Mikulikova L, Matous-Malbohan I, Benesova O, Zwinger A. Prevalence of various antiphospholipid antibodies in pregnant women. Physiological research. 2000;49(3):299-306.
25. Hradecky L, Subrt I, Ulcova-Gallova Z. Urgent termination of pregnancy in pre-eclampsia and panel of antiphospholipid antibodies. American Journal of Reproductive Immunology. 2009;62(6):412-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
